Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / App Notes / 2019 / Tracking Fate and Purge of Impurities and Calculating Carryover

Tracking Fate and Purge of Impurities and Calculating Carryover

02/21/2019

Share

Featured Image

The purpose of process development in pharma is to select and optimize a synthetic route to produce the active pharmaceutical ingredient (API) by the safest, cheapest, fastest, and cleanest (by green chemistry where possible) route, following both Good Laboratory Practice (GLP) and Quality by Design (QbD) principles. As with any synthetic process impurities are generated, and for API development it is mandated by regulatory authorities (e.g., Federal Drug Agency—FDA, European Medicines Agency—EMA, etc.) that impurities are tracked and identified above a certain threshold, while genotoxic and mutagenic impurities must be reported at any level (as stated in the ICH Q7 guideline1).

Route scouting data, in process development, is typically stored in electronic notebooks. Associated analytical information may be accessible as PDF images stored within an experiment record. Unfortunately, however, from the perspective of entity characterization and review, the analytical data is not dynamically linked with the individual stage(s) of the process route and is unsearchable and inaccessible.

Effective management of API development data, and particularly impurity tracking, is necessary for the development of an optimal impurity control strategy. In order to successfully track the fate and purge of impurities, many scientists currently gather LC/MS and LC area percent values for impurity entities in MS Excel® spreadsheets, in lieu of chemically intelligent software to manage this data. While spreadsheets are effective for handling and managing numerical data—helping formulate and understand relationships through sorting and plotting—they are a weak tool for relating chemical structures with the analytical spectra and chromatograms used to identify and characterize them. For example, Excel is unable to generate an impurity map from the synthetic route or calculate purge factor from the available analytical data.

Here, we discuss Luminata™—software designed to help project teams assemble synthetic routes, associated impurities, and all relevant analytical data for process development in a systematized and searchable manner. Luminata enables effective inter- and intra-departmental collaboration and automatically calculates purge factors directly from LC/MS and LC data. In this document, we focus on two manual and often tedious workflows: process optimization and fate & purge calculations.

>> Download the full Application Note as PDF

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Ionic impurities in drug products – USP proposes new ion chromatography method
Ionic impurities in drug products – USP proposes new ion chromatography method

January 21, 2019

Chloride and sulfate are common impurities present in drug substances and drug products...

Decoding Dangerous Drinks with a Spectral Sensor
Decoding Dangerous Drinks with a Spectral Sensor

January 24, 2019

Have you ever heard that moonshine will make you go blind? Today, even your favorite, top-shelf liquor may be just as much of a risk...

Volume Fraction Determination of Ethanol in Splash-Blended Fuel Mixture
Volume Fraction Determination of Ethanol in Splash-Blended Fuel Mixture

January 24, 2019

While electric vehicles are becoming more mainstream the use of traditional gasoline engines will have a place in society for decades to come...

Cleaning Up IPA Production with Stage-by-Stage MIR Analysis
Cleaning Up IPA Production with Stage-by-Stage MIR Analysis

January 24, 2019

2-Propanol is one of the most common solvents in the world, with over 2 million tons produced in 2003 (Science)...

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.